Driehaus Capital RZLT Position
Exited4-Fund ConvergenceDriehaus Capital exited their position in Rezolute, Inc. (RZLT) in Q4 2025, after holding the stock for 3 quarters.
The position was first reported in Q2 2025 and has been tracked across 3 quarterly 13F filings.
RZLT is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Ersodetug in 532 days (Sep 30, 2027), making the timing of Driehaus's position particularly relevant.
Short interest stands at 26.7% of float with 8.3 days to cover, indicating significant bearish positioning against the stock.
1 insider purchase totaling $29K has been filed in the last 90 days, providing an additional conviction signal.
About Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Full company profile →Short Interest
26.7%
8.3 days to cover
Insider Buys (90d)
1
$29K total
Driehaus Capital RZLT Position History
Frequently Asked Questions
Does Driehaus Capital own RZLT?
No. Driehaus Capital exited their position in Rezolute, Inc. (RZLT) in Q4 2025. They previously held the stock for 3 quarters.
How many hedge funds own RZLT?
4 specialist biotech hedge funds currently hold RZLT, including RA Capital Management, Commodore Capital, BVF Partners and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy RZLT?
Driehaus Capital's position in RZLT was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's RZLT position increasing or decreasing?
Driehaus Capital completely exited their RZLT position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
RZLTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →